182.98 0.00 (0.00%)
After hours: 4:39PM EST
|Bid||174.30 x 500|
|Ask||174.42 x 200|
|Day's Range||182.14 - 184.30|
|52 Week Range||152.16 - 201.23|
|PE Ratio (TTM)||68.02|
|Earnings Date||Apr 24, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||5.28 (2.88%)|
|1y Target Est||195.67|
It is our opinion that today’s well-known fact is tied to the faith the stock market has in the ability of technology companies to continue their amazing momentum
NEW YORK, Feb. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SunCoke ...
Something odd has been happening to short-term bank bonds. So far this month, spreads on banks' two-year bonds have widened by more than 15 basis points, according to Bank of America Merrill Lynch. For ...
Novartis: What Are the Major Growth Drivers for 2018? On November 6, 2017, Novartis (NVS) announced positive data from the MEASURE 1 trial, which highlighted the potential of Cosentyx in preventing the progression of disease in the majority of the patients with ankylosing spondylitis. According to the Arthritis Foundation, “Spondyloarthritis is an umbrella term for inflammatory diseases that involve both the joints and the entheses (the sites where the ligaments and tendons attach to the bones).
Novartis: What Are the Major Growth Drivers for 2018? On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients.
Novartis: What Are the Major Growth Drivers for 2018? On January 16, 2018, Novartis (NVS) released data from its Phase 3b trial, CLARITY. This release highlighted the superiority of Cosentyx compared to Johnson & Johnson’s (JNJ) Stelara in clearing skin in patients with moderate to severe psoriasis at the end of 12 weeks and 16 weeks of therapy.
Novartis: What Are the Major Growth Drivers for 2018? In 4Q17, Novartis’s (NVS) Cosentyx reported global sales of $615.0 million, which is a year-over-year (or YoY) increase of 53.0% on a constant currency basis and 11.0% growth quarter-over-quarter. This growth was driven by the drug’s rapid uptake in all approved indications and in all geographies, with a focus on the US and Europe.
What Led to Stellar Rise of AMAG Pharmaceuticals in February? AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company with a focus on clinical research and the development of therapeutics. AMAG also provides services for preserving umbilical cord stem cells and cord tissue units through cord blood registry.
The future of the expensive new cholesterol drugs largely depends on the results of the Sanofi/Regeneron ODYSSEY Outcomes trial coming out next month.
Yahoo Finance’s Seana Smith, Rick Newman and Dion Rabouin discuss a new report by the Centers for Medicare and Medicaid Services that finds spending on health will most likely rise by considerably more than inflation or GDP growth.